US20050276830A1 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders - Google Patents

Compounds, formulations, and methods for treating or preventing inflammatory skin disorders Download PDF

Info

Publication number
US20050276830A1
US20050276830A1 US11/137,911 US13791105A US2005276830A1 US 20050276830 A1 US20050276830 A1 US 20050276830A1 US 13791105 A US13791105 A US 13791105A US 2005276830 A1 US2005276830 A1 US 2005276830A1
Authority
US
United States
Prior art keywords
pharmaceutically acceptable
topical composition
independently hydrogen
alkyl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/137,911
Other languages
English (en)
Inventor
Jack DeJovin
Thomas Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANS ROSA PHARMACEUTICAL DEVELOPMENT Inc
Galderma Laboratories LP
Original Assignee
SANS ROSA PHARMACEUTICAL DEVELOPMENT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33457481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050276830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/137,911 priority Critical patent/US20050276830A1/en
Application filed by SANS ROSA PHARMACEUTICAL DEVELOPMENT Inc filed Critical SANS ROSA PHARMACEUTICAL DEVELOPMENT Inc
Assigned to SANS ROSA PHARMACEUTICAL DEVELOPMENT, INC. reassignment SANS ROSA PHARMACEUTICAL DEVELOPMENT, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROSSI, THOMAS M., DEJOVIN, JACK
Publication of US20050276830A1 publication Critical patent/US20050276830A1/en
Assigned to GALDERMA LABORATORIES INC. reassignment GALDERMA LABORATORIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLLAGENEX PHARMACEUTICALS, INC.
Priority to US12/545,638 priority patent/US8426410B2/en
Priority to US12/620,982 priority patent/US20100130502A1/en
Assigned to GALDERMA LABORATORIES INC. reassignment GALDERMA LABORATORIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLLAGENEX PHARMACEUTICALS, INC.
Priority to US13/545,566 priority patent/US8557817B2/en
Priority to US13/775,861 priority patent/US8993571B2/en
Priority to US13/775,784 priority patent/US8859551B2/en
Priority to US14/672,704 priority patent/US20150202202A1/en
Priority to US15/091,703 priority patent/US20160220565A1/en
Priority to US15/486,353 priority patent/US20170216282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
US11/137,911 2003-05-27 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders Abandoned US20050276830A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/137,911 US20050276830A1 (en) 2003-05-27 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US12/545,638 US8426410B2 (en) 2003-05-27 2009-08-21 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US12/620,982 US20100130502A1 (en) 2003-05-27 2009-11-18 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US13/545,566 US8557817B2 (en) 2003-05-27 2012-07-10 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,784 US8859551B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,861 US8993571B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US14/672,704 US20150202202A1 (en) 2003-05-27 2015-03-30 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US15/091,703 US20160220565A1 (en) 2003-05-27 2016-04-06 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US15/486,353 US20170216282A1 (en) 2003-05-27 2017-04-13 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47361103P 2003-05-27 2003-05-27
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US11/137,911 US20050276830A1 (en) 2003-05-27 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10/853,585 Continuation US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US10/853,585 Division US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US57414204P Continuation 2003-05-27 2004-05-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/545,638 Division US8426410B2 (en) 2003-05-27 2009-08-21 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Publications (1)

Publication Number Publication Date
US20050276830A1 true US20050276830A1 (en) 2005-12-15

Family

ID=33457481

Family Applications (13)

Application Number Title Priority Date Filing Date
US10/853,585 Active 2025-08-25 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US11/137,911 Abandoned US20050276830A1 (en) 2003-05-27 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US11/321,093 Abandoned US20060171974A1 (en) 2003-05-27 2005-12-29 Compounds, formulations, and methods for treating or preventing rosacea
US11/449,079 Active 2027-09-03 US7838563B2 (en) 2003-05-27 2006-06-08 Compounds, formulations, and methods for ameliorating telangiectasias
US12/544,663 Active 2025-05-24 US8231885B2 (en) 2003-05-27 2009-08-20 Compounds, formulations, and methods for ameliorating telangiectasis
US12/545,638 Active 2024-09-10 US8426410B2 (en) 2003-05-27 2009-08-21 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US12/620,982 Abandoned US20100130502A1 (en) 2003-05-27 2009-11-18 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US13/545,566 Active US8557817B2 (en) 2003-05-27 2012-07-10 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,784 Active 2025-01-10 US8859551B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,861 Active US8993571B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US14/672,704 Abandoned US20150202202A1 (en) 2003-05-27 2015-03-30 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US15/091,703 Abandoned US20160220565A1 (en) 2003-05-27 2016-04-06 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US15/486,353 Abandoned US20170216282A1 (en) 2003-05-27 2017-04-13 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/853,585 Active 2025-08-25 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea

Family Applications After (11)

Application Number Title Priority Date Filing Date
US11/321,093 Abandoned US20060171974A1 (en) 2003-05-27 2005-12-29 Compounds, formulations, and methods for treating or preventing rosacea
US11/449,079 Active 2027-09-03 US7838563B2 (en) 2003-05-27 2006-06-08 Compounds, formulations, and methods for ameliorating telangiectasias
US12/544,663 Active 2025-05-24 US8231885B2 (en) 2003-05-27 2009-08-20 Compounds, formulations, and methods for ameliorating telangiectasis
US12/545,638 Active 2024-09-10 US8426410B2 (en) 2003-05-27 2009-08-21 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US12/620,982 Abandoned US20100130502A1 (en) 2003-05-27 2009-11-18 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US13/545,566 Active US8557817B2 (en) 2003-05-27 2012-07-10 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,784 Active 2025-01-10 US8859551B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US13/775,861 Active US8993571B2 (en) 2003-05-27 2013-02-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US14/672,704 Abandoned US20150202202A1 (en) 2003-05-27 2015-03-30 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US15/091,703 Abandoned US20160220565A1 (en) 2003-05-27 2016-04-06 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders
US15/486,353 Abandoned US20170216282A1 (en) 2003-05-27 2017-04-13 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders

Country Status (22)

Country Link
US (13) US7439241B2 (US20050276830A1-20051215-C00018.png)
EP (3) EP2815748B1 (US20050276830A1-20051215-C00018.png)
CN (4) CN101816793B (US20050276830A1-20051215-C00018.png)
AT (1) ATE530185T1 (US20050276830A1-20051215-C00018.png)
AU (1) AU2004242967C1 (US20050276830A1-20051215-C00018.png)
CA (1) CA2530938C (US20050276830A1-20051215-C00018.png)
CY (3) CY1112242T1 (US20050276830A1-20051215-C00018.png)
DK (3) DK2815748T3 (US20050276830A1-20051215-C00018.png)
ES (3) ES2547336T3 (US20050276830A1-20051215-C00018.png)
HK (3) HK1084591A1 (US20050276830A1-20051215-C00018.png)
HR (1) HRP20150957T1 (US20050276830A1-20051215-C00018.png)
HU (3) HUE027616T2 (US20050276830A1-20051215-C00018.png)
IL (1) IL172612A (US20050276830A1-20051215-C00018.png)
LT (1) LT2815748T (US20050276830A1-20051215-C00018.png)
LU (1) LU92462I2 (US20050276830A1-20051215-C00018.png)
MX (1) MXPA05014107A (US20050276830A1-20051215-C00018.png)
NO (1) NO333468B1 (US20050276830A1-20051215-C00018.png)
NZ (1) NZ544300A (US20050276830A1-20051215-C00018.png)
PL (3) PL2388007T4 (US20050276830A1-20051215-C00018.png)
PT (3) PT2388007E (US20050276830A1-20051215-C00018.png)
SI (3) SI2815748T1 (US20050276830A1-20051215-C00018.png)
WO (1) WO2004105703A2 (US20050276830A1-20051215-C00018.png)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165079A1 (en) * 2004-01-22 2005-07-28 Shanler Stuart D. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
US20080207628A1 (en) * 2003-06-25 2008-08-28 Gil Daniel W Methods of preventing and reducing the severity of stress-associated conditions
US20090130027A1 (en) * 2007-11-16 2009-05-21 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment
US20110118267A1 (en) * 2009-11-19 2011-05-19 Galderma Laboratories, L.P. Method and Kit for Treating or Preventing Psoriasis
WO2011061252A2 (en) 2009-11-18 2011-05-26 Galderma Research & Development Combination therapy for treating or preventing an inflammatory skin disorder
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
WO2012001065A2 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20160067222A1 (en) * 2010-11-16 2016-03-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US9554988B2 (en) 2010-06-30 2017-01-31 Galderma Research & Development Method for preventing or treating skin tumor
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
RU2648439C2 (ru) * 2011-02-15 2018-03-26 Аллерган, Инк. Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
US10195180B2 (en) 2011-10-05 2019-02-05 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US10201517B2 (en) 2010-10-21 2019-02-12 Galderma Laboratories, L.P. Brimonidine gel compositions and methods of use
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US11331306B2 (en) 2011-11-21 2022-05-17 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20080095735A1 (en) * 2005-01-31 2008-04-24 Kross Robert D Skin-Protective Polymer For Use In Teat Care Compositions
DE202005002183U1 (de) 2005-02-04 2005-04-14 Beiersdorf Ag Hautverwöhnende Cremelotion
WO2006105450A2 (en) * 2005-03-30 2006-10-05 Revance Therapeutics, Inc. Compositions and methods for treating acne
DK2656860T3 (da) 2005-06-17 2021-07-26 Wisconsin Alumni Res Found Topikale vasokonstriktorpræparater og fremgangsmåder til beskyttelse af celler under cancer kemoterapi og strålingsterapi
WO2007002447A2 (en) * 2005-06-23 2007-01-04 Bioform Medical, Inc. Compositions for treating rosacea
FR2894474B1 (fr) * 2005-12-12 2008-04-11 Galderma Res & Dev Gel depigmentant hydroalcoolique
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US20090060852A1 (en) * 2007-07-27 2009-03-05 Jack Dejovin Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8293742B2 (en) 2008-08-01 2012-10-23 Alpha Synergy Development, Inc. Preferential vasoconstriction compositions and methods of use
US20160184354A1 (en) * 2009-01-23 2016-06-30 Jr Chem, Llc Rosacea treatments and kits for performing them
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
WO2010132882A2 (en) * 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010136585A2 (en) * 2009-05-29 2010-12-02 Galderma Research & Development Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid
CA2810267A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
DK2645993T3 (en) * 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
MX362101B (es) 2010-12-20 2019-01-07 Colgate Palmolive Co Composición de cuidado bucal encapsulada con gelatina que contiene agente de estructura hidrofóbico, ingrediente activo hidrofilico, y portador de aceite.
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
CN102260608B (zh) * 2011-06-23 2012-07-04 江苏安惠生物科技有限公司 灵芝肥皂及其制备方法
JP2014523908A (ja) * 2011-07-14 2014-09-18 アラーガン インコーポレイテッド オキシメタゾリンのゲル組成物および使用方法
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
KR20140091544A (ko) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 모세혈관종 치료방법
KR20140091543A (ko) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2787970B1 (en) 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
WO2013115844A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20150098675A (ko) * 2012-12-24 2015-08-28 라모트 앳 텔-아비브 유니버시티 리미티드 넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법
RU2015148910A (ru) 2013-05-06 2017-06-13 Аллерган, Инк. Альфа-адренергические агонисты для лечения повреждения тканей
BR112016001677A2 (pt) * 2013-07-26 2017-09-19 Galderma Res & Dev Método para a redução ou inibição da progressão de um espessamento da pele em um indivíduo com essa necessidade e método para a regulação de uma resposta de egfr em um indivíduo com essa necessidade
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
JP6188933B2 (ja) 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP2962689B1 (en) 2014-06-30 2018-04-11 Galderma S.A. Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
RU2560698C1 (ru) * 2014-08-15 2015-08-20 Общество с ограниченной ответственностью "Уральский медико-химический центр" (ООО "УМХЦ") Средство наружной терапии больных акне
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3319607A4 (en) 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
WO2017085226A1 (en) * 2015-11-17 2017-05-26 Galderma Sa Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
WO2017161432A1 (pt) * 2016-03-22 2017-09-28 Doris Maria Hexsel Uso de uma composição farmacêutica destinada ao tratamento do eritema cutâneo das poiquilodermias
US10744135B2 (en) * 2016-06-28 2020-08-18 Doris Maria HEXSEL Use of an active substance in the treatment of melasma
CN109265448B (zh) * 2018-11-15 2020-09-15 三峡大学 一类含叔丁基的n-咪唑乙酰基二氢喹喔啉类衍生物，合成方法及其作为杀菌剂上的应用
US10945987B2 (en) 2019-02-19 2021-03-16 Sol-Gel Technologies Ltd. Method for providing early onset of action in the treatment of rosacea
IL287130B (en) 2019-05-01 2022-08-01 Clexio Biosciences Ltd Methods for treating itching
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
JP2023539595A (ja) * 2020-08-26 2023-09-15 オティカラ，インコーポレーテッド 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法
RU2766973C1 (ru) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US3723432A (en) * 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
US3736297A (en) * 1971-04-21 1973-05-29 Labofina Sa Acylation of pyrazole containing polymers
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US3890319A (en) * 1972-02-29 1975-06-17 Pfizer (2-imidazolin-2-y(amino) substituted quinolines, -quinoxalines and -quinazolines as antihypertensive agents
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5424078A (en) * 1988-11-29 1995-06-13 Allergan, Inc. Aqueous ophthalmic formulations and methods for preserving same
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US5552403A (en) * 1993-10-13 1996-09-03 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6534048B1 (en) * 1999-10-26 2003-03-18 Curatek Pharmaceuticals Holding, Inc. Topical clonidine preparation
US20030068343A1 (en) * 2001-10-05 2003-04-10 Neelam Muizzuddin Anti-irritating rosacea treatment
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20040254252A1 (en) * 2003-05-15 2004-12-16 Engles Charles R. Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde and their use in treatments
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050165079A1 (en) * 2004-01-22 2005-07-28 Shanler Stuart D. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
DE2924005C2 (de) * 1979-06-13 1984-07-05 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Isosorbiddinitrat enthaltendes Mittel
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
US5292517A (en) * 1992-02-25 1994-03-08 Allergan, Inc. pH sensitive, reversible gelling, copolymeric erodible drug delivery system
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
EP0969790A2 (de) 1997-02-21 2000-01-12 Beiersdorf Aktiengesellschaft Zubereitungen für die behandlung von rosacea
ES2245028T3 (es) * 1997-04-10 2005-12-16 Agennix, Inc. Uso de lactoferrina en el tratamiento de trastornos inducidos por alergenos.
JPH1129482A (ja) 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
US6513247B1 (en) * 1997-05-29 2003-02-04 Ariel Krasik-Geiger Calibrated angle and depth scissors
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
IN185228B (US20050276830A1-20051215-C00018.png) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
PL357555A1 (en) * 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
HUP0303197A3 (en) 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
AU2001295359A1 (en) 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea
TNSN02063A1 (en) * 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) * 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US7704530B2 (en) * 2001-09-14 2010-04-27 Kenji Nakamura Antimicrobially treated material and methods of preventing coloring thereof
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
FR2862537B1 (fr) † 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
AU2007219040B2 (en) * 2006-02-20 2012-01-19 Commonwealth Scientific And Industrial Research Organisation Method and composition for priming wood and natural fibres
CN101795677B (zh) * 2007-05-09 2012-11-14 沙路特里亚制药有限责任公司 用于治疗炎性病症的螺环化合物
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
MX2012010824A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Patent Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3723432A (en) * 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US3736297A (en) * 1971-04-21 1973-05-29 Labofina Sa Acylation of pyrazole containing polymers
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US3890319A (en) * 1972-02-29 1975-06-17 Pfizer (2-imidazolin-2-y(amino) substituted quinolines, -quinoxalines and -quinazolines as antihypertensive agents
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US5424078A (en) * 1988-11-29 1995-06-13 Allergan, Inc. Aqueous ophthalmic formulations and methods for preserving same
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5300504A (en) * 1989-10-12 1994-04-05 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5373010A (en) * 1989-10-12 1994-12-13 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5418234A (en) * 1989-10-12 1995-05-23 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US5714486A (en) * 1993-10-13 1998-02-03 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5756503A (en) * 1993-10-13 1998-05-26 Allergan Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives
US5773440A (en) * 1993-10-13 1998-06-30 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5703077A (en) * 1993-10-13 1997-12-30 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5587376A (en) * 1993-10-13 1996-12-24 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5561132A (en) * 1993-10-13 1996-10-01 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5552403A (en) * 1993-10-13 1996-09-03 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6465464B2 (en) * 1995-06-28 2002-10-15 Allergan, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6248741B1 (en) * 1995-06-28 2001-06-19 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6534048B1 (en) * 1999-10-26 2003-03-18 Curatek Pharmaceuticals Holding, Inc. Topical clonidine preparation
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US20030068343A1 (en) * 2001-10-05 2003-04-10 Neelam Muizzuddin Anti-irritating rosacea treatment
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
US20040254252A1 (en) * 2003-05-15 2004-12-16 Engles Charles R. Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde and their use in treatments
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050165079A1 (en) * 2004-01-22 2005-07-28 Shanler Stuart D. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586586B2 (en) 2003-05-27 2013-11-19 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7977335B2 (en) 2003-06-25 2011-07-12 Allergan, Inc. Methods of preventing and reducing the severity of stress-associated conditions
US20080207628A1 (en) * 2003-06-25 2008-08-28 Gil Daniel W Methods of preventing and reducing the severity of stress-associated conditions
US20050165079A1 (en) * 2004-01-22 2005-07-28 Shanler Stuart D. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
US8877793B2 (en) 2004-01-22 2014-11-04 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20100233109A1 (en) * 2004-01-22 2010-09-16 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20110027201A1 (en) * 2004-01-22 2011-02-03 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
US20110034423A1 (en) * 2004-01-22 2011-02-10 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
US8815929B2 (en) 2004-01-22 2014-08-26 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US8420688B2 (en) 2004-01-22 2013-04-16 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US20090130027A1 (en) * 2007-11-16 2009-05-21 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
US8114898B2 (en) 2007-11-16 2012-02-14 Allergan, Inc. Compositions and methods for treating purpura
US8673953B2 (en) 2007-11-16 2014-03-18 Allergan, Inc. Compositions and methods for treating purpura
US20110224215A1 (en) * 2007-12-21 2011-09-15 Galderma Laboratories, Inc. Pre-surgical treatment
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
AU2010320911B2 (en) * 2009-11-18 2013-09-12 Galderma Research & Development Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
WO2011061252A3 (en) * 2009-11-18 2011-11-17 Galderma Research & Development Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
US9186358B2 (en) 2009-11-18 2015-11-17 Galderma Laboratories, L.P. Combination therapy for treating or preventing an inflammatory skin disorder
CN102655881A (zh) * 2009-11-18 2012-09-05 盖尔德马研究及发展公司 用于治疗或预防炎性皮肤病症的α2肾上腺素能受体激动剂和非甾体抗炎药的组合
EP2329849A1 (en) 2009-11-18 2011-06-08 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
WO2011061252A2 (en) 2009-11-18 2011-05-26 Galderma Research & Development Combination therapy for treating or preventing an inflammatory skin disorder
WO2011075267A1 (en) 2009-11-19 2011-06-23 Galderma Laboratories Lp Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
US9072739B2 (en) 2009-11-19 2015-07-07 Galderma Laboratories, L.P. Method for treating psoriasis
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US20110118267A1 (en) * 2009-11-19 2011-05-19 Galderma Laboratories, L.P. Method and Kit for Treating or Preventing Psoriasis
US9655991B2 (en) 2010-01-13 2017-05-23 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US10449268B2 (en) 2010-01-13 2019-10-22 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US9861631B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8513249B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9861632B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
WO2012001065A2 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
CN103209691A (zh) * 2010-06-30 2013-07-17 盖尔德马研究及发展公司 α-肾上腺素能受体激动剂用于预防或治疗皮肤肿瘤的用途
US9554988B2 (en) 2010-06-30 2017-01-31 Galderma Research & Development Method for preventing or treating skin tumor
US8163725B1 (en) 2010-10-21 2012-04-24 Galderma R&D SNC Gel compositions and methods of use
US10201517B2 (en) 2010-10-21 2019-02-12 Galderma Laboratories, L.P. Brimonidine gel compositions and methods of use
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US20160067222A1 (en) * 2010-11-16 2016-03-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
RU2648439C2 (ru) * 2011-02-15 2018-03-26 Аллерган, Инк. Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
US10195180B2 (en) 2011-10-05 2019-02-05 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US11331306B2 (en) 2011-11-21 2022-05-17 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations

Also Published As

Publication number Publication date
US20060264515A1 (en) 2006-11-23
HUS1400029I1 (hu) 2017-10-30
EP2815748A1 (en) 2014-12-24
US20130172358A1 (en) 2013-07-04
WO2004105703A3 (en) 2005-03-17
US20100021402A1 (en) 2010-01-28
PL1631293T3 (pl) 2012-03-30
US8557817B2 (en) 2013-10-15
EP1631293A4 (en) 2009-05-06
EP1631293B1 (en) 2011-10-26
ES2376172T5 (es) 2015-01-08
SI1631293T1 (sl) 2012-02-29
DK2388007T3 (en) 2015-09-28
US8426410B2 (en) 2013-04-23
CY2014028I2 (el) 2015-12-09
US8993571B2 (en) 2015-03-31
NZ544300A (en) 2009-03-31
HK1084591A1 (en) 2006-08-04
ATE530185T1 (de) 2011-11-15
LU92462I2 (fr) 2015-11-02
US20170216282A1 (en) 2017-08-03
CN101816793A (zh) 2010-09-01
HUE027616T2 (en) 2016-11-28
DK1631293T3 (da) 2012-02-13
US20060171974A1 (en) 2006-08-03
EP2388007A1 (en) 2011-11-23
AU2004242967B2 (en) 2009-05-28
EP2388007B1 (en) 2015-06-24
MXPA05014107A (es) 2006-03-17
SI2815748T1 (sl) 2020-11-30
US7838563B2 (en) 2010-11-23
CY1112242T1 (el) 2015-12-09
SI1631293T2 (sl) 2015-02-27
PL2388007T4 (pl) 2016-03-31
US20130172359A1 (en) 2013-07-04
HUE051833T2 (hu) 2021-03-29
US20160220565A1 (en) 2016-08-04
PT2815748T (pt) 2020-08-31
CA2530938A1 (en) 2004-12-09
PT1631293E (pt) 2012-02-01
CN101816793B (zh) 2012-08-15
CY1123393T1 (el) 2021-12-31
PT2388007E (pt) 2015-10-14
AU2004242967C1 (en) 2015-12-24
DK1631293T4 (en) 2015-01-12
HRP20150957T1 (hr) 2015-11-20
US8231885B2 (en) 2012-07-31
US7439241B2 (en) 2008-10-21
HK1164126A1 (en) 2012-09-21
CA2530938C (en) 2011-12-13
CN102743380B (zh) 2015-08-12
WO2004105703A2 (en) 2004-12-09
US20040242588A1 (en) 2004-12-02
ES2812532T3 (es) 2021-03-17
CY2014028I1 (el) 2015-12-09
DK2815748T3 (da) 2020-08-24
CN1829518A (zh) 2006-09-06
CN1829518B (zh) 2010-09-08
US20150202202A1 (en) 2015-07-23
US20100227867A1 (en) 2010-09-09
SI2388007T1 (sl) 2016-01-29
EP1631293A2 (en) 2006-03-08
CN102743380A (zh) 2012-10-24
PL2815748T3 (pl) 2020-11-16
ES2376172T3 (es) 2012-03-09
NO20056104L (no) 2006-02-03
US20100130502A1 (en) 2010-05-27
CN101380321B (zh) 2013-03-27
EP2815748B1 (en) 2020-08-05
US20120277241A1 (en) 2012-11-01
HK1204996A1 (en) 2015-12-11
PL2388007T3 (pl) 2016-01-29
NO333468B1 (no) 2013-06-17
EP1631293B2 (en) 2014-10-08
IL172612A (en) 2013-03-24
PL1631293T5 (pl) 2015-04-30
AU2004242967A1 (en) 2004-12-09
US8859551B2 (en) 2014-10-14
ES2547336T3 (es) 2015-10-05
CN101380321A (zh) 2009-03-11
LT2815748T (lt) 2020-11-25

Similar Documents

Publication Publication Date Title
US8993571B2 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
AU2005247467B2 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANS ROSA PHARMACEUTICAL DEVELOPMENT, INC., PENNSY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEJOVIN, JACK;ROSSI, THOMAS M.;REEL/FRAME:016838/0760;SIGNING DATES FROM 20050215 TO 20050715

AS Assignment

Owner name: GALDERMA LABORATORIES INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:021328/0949

Effective date: 20080729

Owner name: GALDERMA LABORATORIES INC.,TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:021328/0949

Effective date: 20080729

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: GALDERMA LABORATORIES INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:027369/0215

Effective date: 20080729